Physician profile
Neil Liebowitz
NPI 1609835362
$6,015.30
in general payments reported to CMS, 2019-2025
22 companies · $31.01 in 2025
The $31.01 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $1,429 · 2021: $2,141 · 2022: $535 · 2024: $15.56 · 2025: $31.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,848.95 | 2019-2022 | |
| Lundbeck LLC | $509.10 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $481.92 | 2019-2021 | |
| Allergan, INC. | $361.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.03 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $221.51 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $193.49 | 2019-2021 | |
| Eisai INC. | $187.68 | 2020-2021 | |
| Abbvie INC. | $148.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $133.29 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.33 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $98.22 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $89.86 | 2019-2021 | |
| Adlon Therapeutics L.P. | $84.04 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $47.20 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $36.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.75 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $16.71 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.56 | 2024 | Xifaxan |
| Noven Therapeutics, LLC | $14.40 | 2020 | |
| Shire North American Group INC | $14.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.30 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Liebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.